/C O R R E C T I O N -- Pegasus/PBN Pharmacal/
PR Newswire
PENSACOLA, Fla., May 18, 2026
In the news release, Liavium®-CA1 (pregabalin chewable tablets) Receives FDA Conditional Approval, Redefining Canine Neuropathic Pain Care, issued 18-May-2026 by Pegasus/PBN Pharmacal over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
Liavium®-CA1 (pregabalin chewable tablets) Receives FDA Conditional Approval, Redefining Canine Neuropathic Pain Care
